BPG is committed to discovery and dissemination of knowledge
Randomized Controlled Trial
©The Author(s) 2025.
World J Gastroenterol. Nov 14, 2025; 31(42): 112577
Published online Nov 14, 2025. doi: 10.3748/wjg.v31.i42.112577
Table 2 Gastrointestinal Symptom Rating Scale total and dimensional scores of study participants before and after intervention, mean ± SD
Variables
Intervention group (n = 89)
Placebo-controlled group (n = 85)
Z
P value
Baseline
    Reflux syndrome3.87 ± 2.133.09 ± 1.43-2.6060.009b
    Abdominal pain syndrome2.76 ± 2.912.44 ± 2.94-0.9990.318
    Dyspepsia5.78 ± 4.614.79 ± 3.71-1.2320.218
    Diarrhea3.76 ± 3.783.13 ± 3.02-0.8760.381
    Constipation2.75 ± 3.502.56 ± 3.34-0.3700.711
    GSRS total score18.67 ± 12.7516.25 ± 10.43-1.0940.274
After 4 weeks of intervention
    Reflux syndrome0.55 ± 1.110.42 ± 1.43-0.8960.370
    Abdominal pain syndrome0.60 ± 0.980.68 ± 1.51-1.2830.196
    Dyspepsia1.71 ± 1.942.05 ± 2.86-0.3620.717
    Diarrhea0.90 ± 1.071.44 ± 1.80-1.3960.163
    Constipation0.88 ± 1.491.32 ± 2.15-1.0270.304
    GSRS total score4.64 ± 4.365.90 ± 7.05-0.3510.726
After 8 weeks of intervention
    Reflux syndrome0.34 ± 1.210.33 ± 1.32-0.0440.965
    Abdominal pain syndrome0.54 ± 1.130.74 ± 1.47-0.2200.826
    Dyspepsia1.41 ± 1.811.97 ± 2.55-1.3080.191
    Diarrhea0.85 ± 1.091.12 ± 1.74-0.0090.314
    Constipation0.80 ± 1.381.05 ± 1.58-1.0270.304
    GSRS total score3.94 ± 4.455.22 ± 6.26-1.0960.273


Write to the Help Desk